BRAINSWAY LTD/S (NASDAQ:BWAY) Stock Rating Lowered by Zacks Investment Research

BRAINSWAY LTD/S (NASDAQ:BWAY) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Friday, Zacks.com reports.

According to Zacks, “BrainsWay Ltd. is a commercial stage medical device company. It is focused on the development and sale of non-invasive neuromodulation products using the Company’s proprietary Deep Transcranial Magnetic Stimulation technology for the treatment of major depressive disorder and obsessive-compulsive disorder. BrainsWay Ltd. is based in Jerusalem, Israel. “

BRAINSWAY LTD/S stock traded down $0.18 during trading hours on Friday, reaching $8.95. 1,000 shares of the stock were exchanged, compared to its average volume of 10,479. BRAINSWAY LTD/S has a 52-week low of $8.00 and a 52-week high of $12.39. The company’s 50 day moving average price is $9.08.

BRAINSWAY LTD/S (NASDAQ:BWAY) last announced its quarterly earnings data on Monday, August 26th. The company reported ($0.17) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.11) by ($0.06). The business had revenue of $5.70 million for the quarter, compared to the consensus estimate of $5.30 million. As a group, equities analysts anticipate that BRAINSWAY LTD/S will post -0.52 EPS for the current year.

Institutional investors have recently made changes to their positions in the business. Delek Group Ltd. purchased a new position in BRAINSWAY LTD/S during the 2nd quarter worth $3,176,000. ARK Investment Management LLC purchased a new position in BRAINSWAY LTD/S during the 2nd quarter worth $863,000. Victory Capital Management Inc. purchased a new position in BRAINSWAY LTD/S during the 2nd quarter worth $157,000. Finally, Noked Capital LTD purchased a new position in BRAINSWAY LTD/S during the 2nd quarter worth $572,000. Institutional investors own 10.84% of the company’s stock.

BRAINSWAY LTD/S Company Profile

Brainsway Ltd. engages in the development and provision of technology solutions for non-invasive treatment of brain disorders in Israel and internationally. It offers deep transcranial magnetic stimulation systems for treating various conditions, including autism, Alzheimer's disease, bipolar disorders, chronic pains, depressive disorders, Parkinson's diseases, schizophrenia, smoking cessation, post-traumatic stress disorders, multiple sclerosis, obsessive compulsive disorders, and stroke rehabilitation.

Further Reading: What is an inverted yield curve?

Get a free copy of the Zacks research report on BRAINSWAY LTD/S (BWAY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for BRAINSWAY LTD/S (NASDAQ:BWAY)

Receive News & Ratings for BRAINSWAY LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BRAINSWAY LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit